Founded in 2009, Bridley is a biotechnology R&D company, which is committed to the research, development and production of biological drugs, pharmaceutical preparations and functional health care products such as blood protein products for pet prevention, treatment and health care, gene engineering expression protein like drugs, biochemical drug preparations and pet vaccines.
The "canine albumin injection" product developed and produced by the company has obtained the registration certificate of national first class new veterinary drug in 2018, which is mainly used for the treatment of canine hypovolemia and canine hypoalbuminemia. In addition, its dog blood immunoglobulin and other products have been approved by the Ministry of Agriculture and Rural Affairs for clinical trials, and dog granulocyte colony stimulating factor (G-CSF), cat granulocyte colony stimulating factor (G-CSF) and cat interferon have applied for national biosafety evaluation. The project has two floors, including indoor decoration, ventilation and air conditioning, electrical construction, process water supply and drainage and automation engineering.